S.3431 - Scleroderma and Fibrosis Research Enhancement Act of 2016114th Congress (2015-2016)
|Sponsor:||Sen. Gillibrand, Kirsten E. [D-NY] (Introduced 09/28/2016)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||Senate - 09/28/2016 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.3431 — 114th Congress (2015-2016)All Information (Except Text)
Introduced in Senate (09/28/2016)
Scleroderma and Fibrosis Research Enhancement Act of 2016
This bill requires the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to establish the National Commission on Scleroderma and Fibrosis Research. (Scleroderma and fibrosis are connective tissue conditions that cause hardening or scarring of skin and organs.)
The commission must develop a long-term, comprehensive plan for scleroderma and fibrosis research. The plan must: (1) prioritize research that has cross-cutting value and requires coordination across NIH, and (2) include specific steps for implementation of the research.
The commission must establish working groups to make research recommendations for the various organs and systems impacted by fibrotic illness.
The commission must be terminated not later than two years after establishment.The NIAMS must create the Scleroderma and Fibrosis Working Group to oversee and assist with implementation of the long-term plan.